Padagis Israel Agencies Ltd

Monoclonal Antibody. Trastuzumab 150 mg, Trastuzumab 420 mg.
Vial:Pwd. for conc. for sol for infus.
Load: 4-8 mg/kg BW
Maint. 2-6 mg/kg BW weekly or at 3 weekly interval, see lit.
Tmt. of pts. with metast. breast cancer who have tumours that overexpress HER2; 1. As a sgle. agent, for the tmt. of those pts. who have received one or more chemother. regimens for their metast. dis..2. In combin. with Paclitaxel or Docetaxel for the tmt. of those pts. who have not received chemother. for their metastatic dis..3. In comb. with an aromatase inhib. for tmt. of postmenopausal ptt. with hne.-receptor posit. metast. breast cancer. See Lit
C/I: Hypersens. Sev. dyspnea at rest.

Local Anesthetic. Bupivacaine (as HCl) 5 mg/ml.
STERILE AMPS: 4 x 4 ml. 3-4 ml (15-20
mg).
Long acting local anesth. for spinal
anesth.

Local Anesthetic. Bupivacaine (as HCl) 5 mg/ml, Glucose Monohydrate 80 mg/ml.
STERILE AMPS: 4 x 4 ml. 3-4 ml (15-20
mg).
Long acting local anesth. for spinal
anesth.

Hair Restorer. Minoxidil 5%.
SOLN: 2 x 60 ml. Apply 1 ml 2 x dly on
scalp. Max. dly dose: 2 ml.
Alopecia androgen. in men.
C/I: Women, hypersens.

Hair Restorer. Minoxidil 5%.
Can: foam for topical use. 60g
1 gram (equiv. to half a capful) applied to a completely dry scalp in men aged 18-49 twice/d. Max dose: 2 g
Hair regrowth tmt. in men
C/I: Hypersens. In women/ in users with treated or untreated HT / in users with any scalp abnormality (incl. psoriasis and sunburn) / in users with a shaved scalp /if occlusive dressings or other topical med. preparations are being used

Lipido Sterolic Extract 160 mg, Polyethylene Glycol 290 mg.
CAPS: 60. 1 cap 2 x dly with meals.
Mod. micturition problems in BPH.
C/I: Hypersens., pre-exis. abd. disord.